简介内容:NoxaBH3, a cysteine-based cross-linked peptide, exhibits enhanced cell permeability and greater inhibitory efficacy against Mcl-1. It binds to the endogenous CXCR4 ligand, resulting in the formation of a ubiquitin-NoxaBH3 conjugate that is subsequently delivered to cancer cells [1].